Ingo Mellinghoff, MD, Oncology, New York, NY, Memorial Sloan-Kettering Cancer Center

IngoK.MellinghoffMDFACP

Oncology New York, NY

Neuro-Oncology

Chair, Department of Neurology, Memorial Sloan Kettering Cancer Center

Dr. Mellinghoff is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Mellinghoff's full profile

Already have an account?

Education & Training

  • UCLA Medical Center
    UCLA Medical CenterFELLOWSHIP
  • UCLA Medical Center
    UCLA Medical CenterRESIDENCY
  • Technical University Munich Faculty of Medicine
    Technical University Munich Faculty of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2008 - 2021
  • CA State Medical License
    CA State Medical License 1997 - 2021

Awards, Honors, & Recognition

  • Member (elected) Association of American Physicians, 2020

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)
    Ingo K Mellinghoff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Press Mentions

  • Kazia Therapeutics Executes Agreement to Begin GBM Agile Pivotal Study
    Kazia Therapeutics Executes Agreement to Begin GBM Agile Pivotal StudyOctober 17, 2020 11:16
  • Kazia Executes Agreement to Commence GBM Agile Pivotal Study
    Kazia Executes Agreement to Commence GBM Agile Pivotal StudyOctober 16, 2020 11:54
  • Early Data Support Further Study of Ivosidenib in mIDH1 Glioma
    Early Data Support Further Study of Ivosidenib in mIDH1 GliomaJuly 18, 2020 10:29
  • Join now to see all

Hospital Affiliations